[go: up one dir, main page]

NO20071604L - Loxapinanaloger og fremgangsmater for anvendelse derav. - Google Patents

Loxapinanaloger og fremgangsmater for anvendelse derav.

Info

Publication number
NO20071604L
NO20071604L NO20071604A NO20071604A NO20071604L NO 20071604 L NO20071604 L NO 20071604L NO 20071604 A NO20071604 A NO 20071604A NO 20071604 A NO20071604 A NO 20071604A NO 20071604 L NO20071604 L NO 20071604L
Authority
NO
Norway
Prior art keywords
methods
loxapine analogs
loxapine
analogs
relates
Prior art date
Application number
NO20071604A
Other languages
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of NO20071604L publication Critical patent/NO20071604L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse beskriver nye forbindelser og fremgangsmåter for anvendelse av disse for modulering av søvn.
NO20071604A 2004-09-21 2007-03-27 Loxapinanaloger og fremgangsmater for anvendelse derav. NO20071604L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
PCT/US2005/034015 WO2006034414A2 (en) 2004-09-21 2005-09-21 Loxapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20071604L true NO20071604L (no) 2007-06-20

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071604A NO20071604L (no) 2004-09-21 2007-03-27 Loxapinanaloger og fremgangsmater for anvendelse derav.

Country Status (19)

Country Link
US (3) US20060063755A1 (no)
EP (1) EP1804804B1 (no)
JP (1) JP5049129B2 (no)
KR (1) KR101264444B1 (no)
AT (1) ATE542536T1 (no)
AU (1) AU2005286713B2 (no)
BR (1) BRPI0515518A (no)
CA (1) CA2580250C (no)
CY (1) CY1112590T1 (no)
DK (1) DK1804804T3 (no)
EA (1) EA012610B1 (no)
ES (1) ES2378452T3 (no)
MA (1) MA28985B1 (no)
MX (1) MX2007003032A (no)
NO (1) NO20071604L (no)
NZ (1) NZ553900A (no)
PL (1) PL1804804T3 (no)
PT (1) PT1804804E (no)
WO (1) WO2006034414A2 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
KR20050092123A (ko) * 2003-01-23 2005-09-20 아카디아 파마슈티칼스 인코포레이티드 Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
ES2324713T3 (es) 2003-12-22 2009-08-13 Acadia Pharmaceuticals Inc. Analogos de diaril(a,d)ciclohepteno amino-sustituidos como agonistas muscarinicos y metodos de tratamiento de trastornos neuropsiquiatricos.
JP2007536216A (ja) * 2004-04-01 2007-12-13 アカディア ファーマシューティカルズ，インコーポレーテッド 固体ｎ−デスメチルクロザピンおよびその結晶形を合成および単離する方法
US7563785B2 (en) * 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
SI2343286T1 (sl) * 2006-10-28 2015-05-29 Methylgene Inc. Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
CA2678897C (en) * 2007-03-15 2015-10-20 Aryx Therapeutics, Inc. Dibenzo[b,f][1,4]oxazapine compounds
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
WO2008114223A1 (en) 2007-03-19 2008-09-25 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
WO2010052579A2 (en) 2008-11-07 2010-05-14 Insuline Medical Ltd. Device and method for drug delivery
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
WO2016154028A1 (en) 2015-03-26 2016-09-29 Iversen Jacqueline M Methods and compositions to inhibit symptoms associated with veisalgia
EP4048667B1 (en) * 2019-10-21 2024-07-03 Alairion, Inc. 3-(4-(11h-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propanoic acid derivatives as h1 and 5-ht2a-receptor modulators for the treatment of sleep disorders
WO2025076527A1 (en) * 2023-10-07 2025-04-10 Inspire Medical Systems, Inc. Pulmonary therapy for sleep disordered breathing care

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (no) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20050049146A1 (en) 2001-11-05 2005-03-03 Chiarello John F. Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
AU2003290079A1 (en) * 2002-12-20 2004-07-14 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
DK1804804T3 (da) 2012-02-20
WO2006034414A2 (en) 2006-03-30
EA200700702A1 (ru) 2007-10-26
US20060063755A1 (en) 2006-03-23
JP2008513510A (ja) 2008-05-01
WO2006034414A3 (en) 2006-09-08
BRPI0515518A (pt) 2008-07-29
CA2580250A1 (en) 2006-03-30
AU2005286713A1 (en) 2006-03-30
EP1804804A2 (en) 2007-07-11
PT1804804E (pt) 2012-03-30
EP1804804B1 (en) 2012-01-25
MA28985B1 (fr) 2007-11-01
JP5049129B2 (ja) 2012-10-17
ES2378452T3 (es) 2012-04-12
PL1804804T3 (pl) 2012-08-31
US7592333B2 (en) 2009-09-22
US20060063928A1 (en) 2006-03-23
AU2005286713B2 (en) 2010-10-28
EP1804804A4 (en) 2010-11-24
EA012610B1 (ru) 2009-10-30
CA2580250C (en) 2013-05-14
MX2007003032A (es) 2007-05-21
KR101264444B1 (ko) 2013-05-20
US20090186872A1 (en) 2009-07-23
US8101596B2 (en) 2012-01-24
ATE542536T1 (de) 2012-02-15
KR20070060126A (ko) 2007-06-12
CY1112590T1 (el) 2016-02-10
NZ553900A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
NL301145I2 (nl) Tirbanibulin
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
MX2007001127A (es) Moduladores de pirrolo-piridina cinasa.
DE602004026113D1 (de) Glp-1-verbindungen
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
UY3493Q (es) Esponja
TW200640924A (en) VEGF-R2 inhibitors and methods
NO20071127L (no) Triazoloftalaziner
SE0301653D0 (sv) Novel compounds
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
ATE412649T1 (de) Substituierte heteroarylbenzofuransäuren
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
UY28344A1 (es) Nuevos compuestos
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DK1492501T3 (da) Fremgangsmåder med anvendelse af lamellare legemer til terapeutiske formål
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
EA200701366A1 (ru) Кислородсодержащие аннелированные фенилпиперазин- и фенилдиазепанкарбоксамиды
EA200700654A1 (ru) Способ очистки глины

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA

FC2A Withdrawal, rejection or dismissal of laid open patent application